Immatics (IMTX) Competitors

Immatics (NASDAQ:IMTX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.

Which has more risk and volatility, IMTX or NAMS?

Immatics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500.

Do analysts recommend IMTX or NAMS?

Immatics currently has a consensus price target of $16.67, suggesting a potential upside of 291.24%. NewAmsterdam Pharma has a consensus price target of $43.33, suggesting a potential upside of 165.20%. Given Immatics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Immatics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
NewAmsterdam Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is IMTX or NAMS more profitable?

NewAmsterdam Pharma has a net margin of 0.00% compared to Immatics' net margin of -47.94%. NewAmsterdam Pharma's return on equity of 0.00% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-47.94%	-15.90%	-9.38%
NewAmsterdam Pharma	N/A	N/A	N/A

Does the media refer more to IMTX or NAMS?

In the previous week, NewAmsterdam Pharma had 4 more articles in the media than Immatics. MarketBeat recorded 8 mentions for NewAmsterdam Pharma and 4 mentions for Immatics. Immatics' average media sentiment score of 1.14 beat NewAmsterdam Pharma's score of 0.65 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of IMTX or NAMS?

64.4% of Immatics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the MarketBeat Community prefer IMTX or NAMS?

Immatics received 4 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.43% of users gave NewAmsterdam Pharma an outperform vote while only 75.61% of users gave Immatics an outperform vote.

Company	Underperform	Outperform
Immatics	Outperform Votes 31 75.61%	Underperform Votes 10 24.39%
NewAmsterdam Pharma	Outperform Votes 27 96.43%	Underperform Votes 1 3.57%

Which has preferable valuation and earnings, IMTX or NAMS?

Immatics has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$155.84M	3.32	-$104.98M	$0.14	30.43
NewAmsterdam Pharma	$45.56M	39.38	-$176.94M	-$2.60	-6.28

Summary

NewAmsterdam Pharma beats Immatics on 10 of the 19 factors compared between the two stocks.